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Background: The relationship between cannabis use and cognitive function in mid-life has 
rarely been examined despite verbal learning deficits in young adults. Method: A 
longitudinal cohort study of 1,897 Australians recruited at 40-46  years of age and followed 
up 4 years (94%) and 8 years (87%) later. Random effects regression was used to assess 
within- and between-person associations between cannabis use and cognitive function across 
waves of data, and examine whether age-related changes in cognitive performance were 
modified by cannabis use. The first list of the California Verbal Learning Test (immediate 
and delayed recall), Symbol Digit Modality Test, Digit Backwards, simple and choice 
reaction time tasks, were administered at each wave. The Spot-the-Word test was used to 
assess premorbid verbal ability. Self-reported cannabis use in the past year (no use, < weekly 
use, ≥ weekly use) was assessed at each wave. Findings: Participants who used cannabis ≥ 
weekly had worse immediate recall (b = -0.68, p = 0.014) and showed a trend toward worse 
delayed recall (b = -0.55, p = 0.062) compared to non-users after adjusting for correlates of 
cannabis use and premorbid verbal ability. These effects were due to between-person 
differences. There were no significant within-person associations between cannabis use and 
recall, nor was there evidence of greater cognitive decline in cannabis users with age. 
Conclusions:  Mid-life cannabis users had poorer verbal recall than non-users, but this was 
not related to their current level of cannabis use, and cannabis was not associated with 
accelerated cognitive decline. 
 





Understanding the impact of cannabis use on cognitive function in mid-life adults is 
increasingly important. Cannabis is already consumed by an estimated 178 million people 
worldwide (United Nations Office on Drugs and Crime, 2015) and 13.1 million people are 
dependent on the drug (Degenhardt et al., 2013). However, its use is projected to rise 
significantly in older cohorts (50+ years) with the ageing of the baby-boomer generation 
(Colliver et al., 2006; Wu and Blazer, 2011). The medicalisation of cannabis is also likely to 
see increased use in older adults to treat chronic pain (Martin-Sanchez et al., 2009) and as an 
antiemetic in cancer treatment (Borgelt et al., 2013).  For example, Pacula et al. (2015) cite 18 
US states where legislation has been established around the medicinal use of cannabis, this 
trend beginning in California in 1996 with the establishment of medical marijuana 
dispensaries.  
 
Most research on the relationship between cannabis use and cognitive function comes from 
studies of young adults (Becker et al., 2010; Block and Ghoneim, 1993; Carlin and Trupin, 
1977; Croft et al., 2001; Dafters et al., 2004; Dougherty et al., 2013; Ehrenreich et al., 1999; 
Fried et al., 2002; Gouzoulis-Mayfrank et al., 2000; Pope et al., 1996; Rodgers, 2000; 
Solowij, 1995). A meta-analysis of this research found that cannabis use was associated with 
worse performance on verbal learning and memory (i.e., immediate and delayed recall on the 
Californian Verbal Learning Test and the Rey Auditory Verbal Learning Test), with effect 
sizes ranging between 0.21 and 0.27, but not on tasks involving attention, executive function, 
motor function, reaction time or language ability (Grant et al., 2003). However, more recent 
research suggests deficits may also be present occur in other domains, including attention and 
concentration and abstract reasoning (Crane et al., 2013). Longitudinal studies have also 
found deficits relative to premorbid ability (Fried et al., 2005; Meier et al., 2012), including 
greater cognitive decline into adulthood (Meier et al., 2012). Although some performance 
decrements recover with cessation of cannabis use (Fried et al., 2005; Tait et al., 2011) full 
recovery is not always observed (Meier et al., 2012).  
 
Few studies have examined how these cognitive deficits manifest in later adulthood, where 
they may be exacerbated by cumulative exposure to cannabis, interact with natural age-
related declines in processing speed  (Anstey et al., 2014; Singh-Manoux et al., 2012), or arise 
from secondary adverse effects of cannabis on educational and vocational attainment 
(Horwood et al., 2010b) — both of which are protective against age-related cognitive decline 
(Anstey et al., 2013).  Both Solowij et al. (2002) and Pope et al. (2001) found verbal learning 
deficits in older cannabis users (aged 32-55 years), compared to a non-using control group; 
however, Pope et al. (2001) found deficits remitted following a 28 day washout period from 
cannabis use, suggesting that deficits may be restricted to periods of heavy use (Pope et al., 
2001).   
 
In this paper we use an alternative approach to previous research by examining within-person 
changes in cognitive function that co-occur with changes in cannabis use in a longitudinal 
cohort. Within-person effects estimate the average change in an outcome (i.e., cognitive test 
performance) during time periods when an individual is exposed to a particular risk factor 
(i.e. cannabis use) relative to when they are not exposed (i.e. not using cannabis).  This 
approach provides superior control for time-invariant factors (e.g., heritable traits, 
personality, sex) than statistical adjustment, and also reduces confounding by unmeasured 
time-invariant confounds (Gunasekara et al., 2014). It has been used to strengthen evidence 
for a causal relationship between substance use and various health and social outcomes 
(Fergusson et al., 2002; Livingston, 2011; McKetin et al., 2013). Time-varying factors can 
still need to be adjusted for because they can confound these types of analyses. 
 
We assessed the relationship between current levels of cannabis use and cognitive functioning 
across three waves of data in a population-based longitudinal cohort of adults in their forties 
and examined whether deficits were restricted to current levels of cannabis use by testing 
within-person changes in cognitive performance during periods of cannabis use.  We 
hypothesised (a) that heavy cannabis users would perform more poorly on tests of verbal 
recall; and (b) that this effect would be due to a significant within-person association between 
cannabis use and cognitive function, indicating worse cognitive function during periods of 
more frequent cannabis use relative to periods of no use. We also explored whether cannabis 
use modified age-related changes in cognitive performance, which could indicate early 
cognitive decline. 
 
2 MATERIAL AND METHODS 
 
2.1 Participants and procedure 
Participants were 2,530 people aged 40-46 years old, who were recruited from the Personality 
and Total Health (PATH) through life cohort in 2000-2001. Participants were randomly 
drawn from the electoral roll of the Australian Capital Territory and Queanbeyan in Australia 
(Anstey et al., 2012). Voting is compulsory in Australia and therefore electoral roll samples 
provide a good reflection of the adult general population. The response rate was 64.6%. A 
comparison with the Australian census data show that the final cohort was representative of 
the general population in terms of their marital and employment status, but that they were 
more educated (Anstey et al., 2012). Participants were followed up every four years, with 
2,354 (93%) re-interviewed at wave 2, and 2,182 at wave 3 (86%).  
 
For this study, participants were excluded if they reported a history of head injury (n = 321), 
stroke or transient ischemic attack (n = 62) or epilepsy (n = 21). Similar to previous studies 
on cognitive function in this cohort (Tait et al., 2011), we excluded participants for whom 
English was a second language (n = 210), because this was related to poor performance on 
verbal recall. A further 18 participants were excluded because they reported illicit 
psychostimulant use at either wave 2 or 3 (this was not assessed at wave 1), and one 
participant was excluded because they were missing data on cannabis use at all three waves. 
This left 1,897 participants in the final sample, with 1,774 followed up at wave 2 (94%) and 
1,653 followed up at wave 3 (87%). Data on cannabis use was missing at seven observation 
points, giving a total of 5,317 observations across all three waves. 
 
All participants were volunteers who provided informed consent prior to participation. The 






Cannabis use: Past year cannabis use was assessed using the question “Have you used 
marijuana/hash in the past 12 months?” followed by the question “How often do you use 
marijuana/hash?” (once a week or more, once a month, every 1-4 months, once or twice a 
year, less often/no longer use). Based on these questions, participants were classified as either 
not using cannabis within the past year (non-users), using cannabis less than weekly use, or 
using cannabis weekly or more often.  
 
Cognitive tests: All cognitive tests were administered at each wave. Immediate and delayed 
recall was assessed with components of the California Verbal Learning Test (Delis et al., 
1987). Participants were read a list of 16 words from 4 taxonomic categories (e.g., fruits, 
tools), presented in unblocked order, and asked to immediately recall as many words as 
possible (immediate recall). This list was read once only. Following a short interval (i.e., 
completing a grip strength task), participants were again asked to recall as many words as 
possible (delayed recall).Working memory was assessed using the Digits Backwards subtest 
of the Wechsler Memory Scale, which involves reading a series of digits to the participant 
who is then required to recall them in reverse order (Wechsler, 1945). The Symbol-Digit 
Modalities Test (Smith, 1982) requires participants to substitute digits (1–9) with their 
corresponding symbol as fast as possible within a 90-second period; it involves attention, 
visual scanning and motor speed (Sheridan et al., 2006) and is sensitive to changes in 
cognitive function following mild head injury (Hinton-Bayre et al., 1997). Simple and choice 
reaction time was measured by getting the participant to press one of two buttons on the top 
of a small box (held in both hands), with their index fingers, in reaction to a red stimulus light 
located on the front of the box under each button. A green get-ready light was centred beneath 
these. The mean simple reaction time was taken from four blocks of 20 trials and the mean 
choice reaction time from two blocks of twenty trials. For simple reaction time participants 
used their right hand regardless of dominance. Premorbid verbal ability was assessed using 
the Spot-the-Word Task (Baddeley et al., 1993). This tests involves presenting the participant 
with 60 consecutive word pairs, each of which contains one real word and one word that is 
not real (e.g. ‘flonty – xylophone’). The participant is required to point to the real word in the 
pair. The Spot-the-Word test is a robust measure of verbal intelligence which is resilient to 
deterioration with age (Baddeley et al., 1993) and mild head injury (Hinton-Bayre et al., 
1997).  
 
Time-invariant co-variates: Time invariant covariates were assessed at wave 1 and included 
age, sex, years of education, race (Caucasian vs. other) and past alcohol consumption. Past 
alcohol consumption was assessed by asking the participant the following questions about 
when they were drinking at their highest level over a period of three months or longer: “How 
often did you have a drink containing alcohol?” (monthly or less, 2 to 4 times a month, 2 to 3 
times a week, 4 or more times a week) and “How many standard drinks did you have on a 
typical day when you were drinking?” (1 or 2, 3 or 4, 5 or 6, 7 to 9, 10 or more). 
  
Time-varying co-variates: Time-varying co-variates were measured at all three waves and 
included employment status (employed vs. not in the labour force), tobacco smoking (never, 
past and current) and alcohol consumption (Alcohol Use Disorders Identification Test 
(AUDIT) (Babor et al., 2001) score). Body mass index (BMI) was calculated using self-
reported height and weight [weight (kg) / height (m)
2
]. Exercise was based on self-reported 
average hours or mild, moderate or vigorous exercise per week. Examples of mild exercise 
were walking, weeding; moderate exercise: dancing, cycling; and, vigorous exercise: running, 
squash. Depression and anxiety were based on scores of  ≥ 5 and ≥ 7 on the Goldberg 
Depression and Anxiety Scales respectively (Goldberg et al., 1988); these cut points correctly 
classified 83% and 85% of people with depressive and generalised anxiety disorders in this 
cohort respectively (Kiely and Butterworth, 2015). 
 
2.3 Statistical analysis 
Analyses were conducted using Stata Special Edition version 14.1 (Statacorp, College 
Station, TX). Analyses were carried out across all three waves of data.  
 
To identify potential confounders we examined the relationship between cannabis use and 
each participant characteristic using a series of regression models where the participant 
characteristic was the outcome variable and level of cannabis use was the predictor (no 
cannabis use [0], < weekly use [1], ≥ weekly use [2]). Linear regression models were used for 
continuous outcomes and logistic regression models were used for categorical outcomes. 
Variables with multiple categories were analysed by creating dichotomous variables that 
compared each category to the lowest (reference) category. When the outcome was time-
varying, random effects regression was used with a random intercept to allow clustering of 
individual-level data on repeated measures across waves of assessment.  Where a random 
intercept could not be fitted because the outcome did not vary across repeats, robust standard 
errors were used. The results of these analyses are shown in Table 1. 
 
To examine the relationship between cannabis use and cognitive function we conducted a 
series of linear random effects regressions, with the time-varying cognitive test measure as 
the outcome variable and the time-varying level of cannabis use (no use [0] – reference 
category, < weekly use [1], ≥ weekly use [2]) as a categorical predictor variable. These 
models included a random intercept to allow clustering of individual-level data on repeated 
assessments. All models included study wave (wave 1 [0], wave 2 [1], wave 3 [2]).  To assess 
whether cannabis use modified age-related changes in cognitive function, an interaction term 
between time-varying cannabis use level (no use [0], < weekly use [1], ≥ weekly use [2]) and 
wave (wave 1 [0], wave 2 [1], wave 3 [2]) was included in the model. Models were adjusted 
for factors significantly associated with cannabis use (age at baseline, sex, unemployment, 
years of education, tobacco smoking, current AUDIT score, heaviest past drinking (4+ 
times/week and number of drinks/day), BMI, depression and premorbid verbal ability (Spot 
the Word score)). For cognitive tests where there was a significant relationship between test 
performance and cannabis use, subsequent within-person and between-person effects of 
cannabis on test performance were conducted using Stata’s fixed and between effects 
estimator options respectively. Mean and 95% confidence intervals for test scores for each 
wave were based on predicted margins from adjusted models.  
 
Neither loss to follow-up nor missing data on cognitive tests (between 5 and 82 cases per test 
at each follow-up) were significantly correlated with cannabis use category (p > 0.05, 
analyses not shown) and so data were assumed to be missing at random and excluded from 




3.1 Characteristics of participants at baseline 
Participants were English speaking (100%), mostly Caucasian (98%) and employed (91%); 
16% were current tobacco smokers and 14% exceeded the cut-off of ≥ 8 for risky drinking on 
the AUDIT (Table 1). Ten per cent of the sample (n = 576) had used cannabis at one of the 
three waves, with cannabis use reported at 6% of all assessments (n = 331), and with 2% (n = 
106) involving using cannabis weekly or more often. Amongst participants who had used 
cannabis, 31% (n = 176) of observations represented a change in cannabis use category since 
the previous wave. Cannabis use was associated with being younger, male, not employed, 
having fewer years of education, smoking tobacco, lower BMI, greater alcohol consumption 
and depression (Table 1). 
 
3.2 Relationship between cannabis use and cognitive performance 
The unadjusted relationship between cannabis use and cognitive test performance across all 
three waves is shown in Table 2. Cannabis use was associated in a dose-related fashion with 
lower scores on immediate and delayed recall. It was also related to lower premorbid verbal 
ability (scores on the Spot the Word test). Cannabis use was not related to other test scores.  
 
3.3 Between- versus within-person effects for cannabis use 
Table 3 shows the relationship between cannabis use and verbal recall, overall, and for 
within- and between-person effects separately. Significant overall and between-person effects 
were found for weekly or greater cannabis use on immediate and delayed recall. Between-
person effects were attenuated by adjustment for factors associated with cannabis use (i.e. 
age, sex, years education, employment, tobacco smoking, AUDIT score, heaviest past 
drinking, BMI and depression) and Spot the Word test scores, but using cannabis weekly or 
more often remained significantly associated with lower test scores on immediate recall 
(Table 3). The adjusted difference between weekly or greater cannabis use and no cannabis 
use was 1.2 and 1.1 words less than for no cannabis use on immediate and delayed recall 
respectively (or 0.55 SD and 0.44 SD respectively). 
 
Within-person effects for cannabis use on immediate and delayed recall were not significant 
(Table 3), suggesting no significant difference in immediate or delayed recall during waves 
when cannabis using participants were using cannabis compared to waves when they were not 
using the drug.  
 
3.4 Changes in cognitive performance with age 
Changes in recall over the three waves of assessment, and interactions between cannabis use 
and wave of assessment, are shown in Table 3. Over the three waves there was small but 
significant improvement in immediate recall and delayed recall; however, there were no 
significant interaction effects between cannabis use level and wave, for either immediate 
recall or delayed recall, indicating that cannabis use did not significantly modify changes in 
recall that occurred with older age.  There were no significant interaction effects between 
wave by cannabis use level for other cognitive tests. The predicted mean immediate and 
delayed recall scores for each wave, adjusted for correlates of cannabis use and premorbid 
verbal ability, are shown in Figure 1.  
 
4 DISCUSSION 
The finding that mid-life cannabis users has worse verbal recall is consistent with past 
research in young adults (Grant et al., 2003); however, this was only evident for a between-
person effect, reflecting an overall average lower performance of heavy cannabis users 
relative to people who do not use the drug. The lack of a significant within-person effect of 
cannabis use on verbal recall indicates that verbal recall was no worse when people were 
using cannabis weekly or more often compared to when they were not using cannabis at all. 
This result is not consistent with cannabis-related deficits being due to the acute 
pharmacological effects of THC, as suggested by Pope et al. (2001) and others (Hanson et al., 
2010), or that deficits recover with abstinence (Meier et al., 2012; Tait et al., 2011). Instead, 
our finding suggests that worse recall in heavy cannabis users is not significantly related to 
current levels of cannabis use. There are several possible interpretations of this result, as 
outline below. 
 
First, decrements in verbal recall could reflect a lasting effect of cannabis use that does not 
recover with abstinence. This interpretation of the data would be consistent with a growing 
body of evidence that exposure to cannabis during adolescence can produce lasting changes 
in brain morphology (Becker et al., 2010; Carey et al., 2015; Mashhoon et al., 2015; 
Shollenbarger et al., 2015) and cognitive function (Becker et al., 2010; Meier et al., 2012; 
Schneider and Koch, 2003). It may be that mid-life cannabis users are suffering lasting effects 
from exposure to the drug during this critical period in adolescent brain development. The 
failure to find a temporal relationship between current levels of cannabis use and cognitive 
function could be because the adult brain is relatively more resistant to cannabis-induced 
neurotoxicity (Schneider and Koch, 2003) or the lack of a close temporal relationship 
between cannabis use/intoxication and cognitive testing in our study.  
 
A second explanation for the lack of a temporal relationship between cannabis use and worse 
recall is that cannabis use may have a lasting effect on cognitive function via its adverse 
effects on outcomes in early adulthood, these including lower educational achievement 
(Horwood et al., 2010a; Horwood et al., 2010b), lower income and greater welfare 
dependence (Horwood et al., 2010a). Although we adjusted for a range of other variables that 
could impact on cognitive function (premorbid verbal ability, schooling, currently 
employment, alcohol and tobacco consumption, body mass index, exercise, anxiety and 
depression) there may have been residual confounding by such factors, or confounding by 
other unmeasured factors. 
 
A third possibility is that verbal recall deficits may pre-date cannabis use, or that the two 
conditions may result from a comorbid vulnerability (e.g. shared genetic or familial factors). 
Evidence to support this possibility comes from a study by Pagliaccio et al. (2015) who 
examined brain volume in cannabis discordant twin/sibling couples, and found that the 
relationship between cannabis use and brain volume was largely owing to shared genetic 
factors rather than exposure to cannabis.  
 
Deficits in cognitive function could also be a reflection of the elevated risk of psychotic 
disorders seen in cannabis users (Hall and Degenhardt, 2008), with cannabis-related brain 
changes being correlated with psychotic symptoms (Yucel et al., 2008). Psychotic disorders 
are also characterised by deficits in episodic memory (Fioravanti et al., 2012; Schaefer et al., 
2013). These deficits are thought to be a neurodevelopmental phenomenon that conveys 
vulnerability to psychotic disorders (Bora and Murray, 2014; Bossong and Niesink, 2010; 
Bowie and Harvey, 2006; Fusar-Poli et al., 2012; Schneider and Koch, 2003). Therefore, 
enduring cognitive deficits in cannabis users could reflect a pre-existing vulnerability to 
psychosis in a subset of this population. 
 
Participants who used cannabis weekly or more often recalled a mean of around one word 
less (a deficit of around one half of a standard deviation less) than non-cannabis users on a list 
of 16 words. According to the DSM-5 (American Psychiatric Association, 2013), a mild 
neurocognitive disorder is characterised by cognitive performance that is least one standard 
deviation below the norm, while dementia requires performance that is at least two standard 
deviations below the norm. Therefore, the average recall deficits seen in people who use 
cannabis weekly or more often appear to fall within the normal range of cognitive 
functioning, and thus do not reflect a clinically significant impairment. However, the net 
effect of this decrement at a population level may be important. Verbal recall is a measure of 
episodic memory, which is the first cognitive symptom of Alzheimer’s disease (Gainotti et 
al., 2014), suggesting mid-life cannabis users are a high risk group for dementia — a risk 
could be circumvented via cognitive remediation and reduction of known modifiable risk 
factors for dementia, such as tobacco smoking (Anstey et al., 2013). 
 
In this study we did not find evidence that cannabis was related to early decline in verbal 
recall. However, we had limited statistical power to detect such an effect due to the small 
number of heavy cannabis users in this sample. We also found no evidence of verbal recall 
decline in the overall sample, suggesting that it may be too early in the life-span to detect any 
effects of cannabis on cognitive decline. Being a highly educated sample, cognitive reserve 
may also be mitigating against any deleterious effect that cannabis may have on cognitive 
decline. Effects on cognitive decline, should they exist, may become apparent with older age. 
 
Limitations and considerations 
The key strength of our findings is that they are based on a large general population sample 
and we were able to adjust for a wide variety of lifestyle and health factors that are related to 
cognitive function. The PATH cohort provides a unique opportunity to examine the 
relationship between cannabis use and cognitive function in mid-life adults, with other 
population-based cannabis research focussing on younger cohorts (e.g., Fergusson and 
Horwood (2000)). However, an inherent limitation of large-scale epidemiological studies is 
reliance on self-report, and detailed measurement is often not possible. We did not have a 
detailed history of participant’s cannabis use, nor did we have information on how recently 
cannabis was used prior to testing, factors that may have obscured the relationship between 
current cannabis use levels and cognitive function. Measures of alcohol and tobacco use were 
more comprehensive, including both current and past use, but the possibility of residual 
confounding remains. Although we relied on self-reported illicit substance use, this is reliable 
when participant confidentiality is assured (Darke, 1998), as it was in this study.  
 
A further consideration is that immediate and delayed recall were assessed using components 
of the California Verbal Learning Test rather than the full test. Therefore scores on the test 
cannot be directly compared to normative data to assess impairment. Also, the delayed recall 
was assessed after only a brief interval rather than the longer delay normally used to assess 
delayed recall in the California Verbal Learning Test. This could explain discrepancies 
between our results and those of previous studies. A longer delay period may have been more 
sensitive to deficits in delayed memory, while the absence of such a delay may have reduced 
our capacity to detect cannabis-related deficits in delayed recall. 
 
Conclusion 
Mid-life cannabis use (≥ weekly use) was associated with worse verbal episodic memory as 
reflected by poor verbal recall. Deficits in verbal recall may place cannabis users at elevated 
risk of cognitive decline in later life, or even dementia, as episodic memory decline is the first 
cognitive symptom of Alzheimer’s disease (Gainotti et al., 2014). Further research is needed 
to establish whether these decrements are due to lasting brain changes associated with 
cannabis use or other correlates of cannabis use (e.g. genetics, vulnerability to psychosis).  
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Table 1. Relationship between cannabis use and participant characteristics across all three waves 
 No use  
(n = 4,986 PY) 
< weekly use  
(n = 225 PY) 
≥ weekly 
(n = 106 PY) 
 Mean (SD)/ n (%) Mean (SE)/ n (%) Mean (SE)/ n (%) 
Demographics at baseline    
 Age  42.6 (1.5) 42.3 (1.5)** 42.7 (1.4) 
 Male 2,119 (42.5) 130 (57.8)*** 74 (69.8)*** 
 Caucasian  4,876 (97.8) 221 (98.2) 105 (99.1) 
 Employed  4,553 (90.9) 204 (90.7) 89 (84.8) 
 Years of education 14.5 (2.3) 14.5 (2.1) 13.9 (2.5)** 
Heaviest past drinking     
 4+ times per week 1,770 (35.5) 122 (54.2)*** 59 (55.7)*** 
 No. drinks/day    
  Up to 2 drinks 2,305 (46.4) 52 (23.4)*** 26 (24.5)*** 
  3-4 drinks 1,389 (28.0) 44 (19.8)** 29 (27.4) 
  5-9 drinks 1,079 (21.7) 105 (47.3)*** 35 (33.0)* 
  10+ drinks 196 (3.9) 21 (9.5)*** 16 (15.1)*** 
AUDIT score 4.2 (3.6) 7.1 (5.2)*** 6.6 (5.7)*** 
Tobacco smoking    
 Non-smoker 2,768 (55.6) 47 (20.9) 12 (11.3) 
 Past smoker 1,544 (31.0) 89 (39.6)  25 (23.6)*** 
 Current smoker 668 (13.4) 89 (39.6) *** 69 (65.1)*** 
Body mass index 27.0 (5.1) 26.4 (4.4)* 25.7 (3.9)**  
Exercise    
 Low 1,815 (37.6) 83 (37.9) 37 (35.2) 
 Moderate 1,891 (39.2) 82 (37.4) 42 (40.0) 
 High 1,123 (23.3) 54 (24.7) 26 (24.8) 
Depression 854 (17.2) 61 (27.4)*** 21 (19.8) 
Anxiety 778 (15.7) 40 (17.9) 10 (9.4) 
* p < .05, ** p < .01 ***p < .001. P values reflect comparisons of each participant characteristic for < 
weekly use and  ≥ weekly use relative to no use across all waves of data. Comparisons were made for 
person years (PY) using regressions with robust standard errors for time-invariant characteristics and 
random effects regressions for time-varying characteristics.
Table 2. Relationship between level of cannabis use and cognitive test scores across all three waves 
 No use (n = 5,006 PY) < weekly use (n = 225 PY) ≥ weekly (n = 106 PY) 
 Mean (SD) Mean (SD) Coefficient 
(SE) 
P value Mean (SD) Coefficient 
(SE) 
P value 
Spot the word  51.4 (5.0) 52.2 (4.1) 0.01 (0.23) .975 51.1 (6.1) -0.92 (0.43) .035 
Immediate recall 8.1 (2.2) 7.7 (2.0) -0.34 (0.14) .017 6.8 (2.1) -1.00 (0.24) < .001 
Delayed recall 7.4 (2.5) 6.9 (2.3) -0.32 (0.15) .035 6.0 (2.2) -0.91 (0.26) < .001 
Digit span backwards 5.6 (2.3) 5.6 (2.5) -0.21 (0.14) .125 5.2 (2.4) -0.38 (0.23) .105 
Symbol Digit Modality Test 60.4 (8.8) 59.7 (8.5) 0.14 (0.43) .741 58.5 (7.9) 0.35 (0.79) .657 
Mean simple reaction time (ms) 233.8 (42.0) 230.8 
(49.6) 
-2.57 (2.70) .341 233.4 (37.5) -1.58 (4.59) .731 
Choice reaction time (ms) 290.8 (40.2) 291.6 
(41.8) 
1.25 (2.43)  .608 298.6 (36.3) 1.54 (4.21) .715 
Coefficients reflect comparisons with no use from random effects regressions across all three waves of data 
 
  
Table 3. Random effect regression models showing the relationship between cannabis use and recall 
 Immediate recall  Delayed recall 
 Unadjusted  Adjusted
a
   Unadjusted  Adjusted
a
  
 Coefficient (SE) P value Coefficient (SE) P value  Coefficient (SE) P value Coefficient (SE) P value 
Random effects          
 Cannabis use          
  No use (ref)          
  < wkly use -0.29 (0.16) .066 -0.28 (0.16) .092  -0.23 (0.17) .162 -0.16 (0.17) .338 
  Wkly+ use -1.00 (0.24) < .001 -0.68 (0.27) .014  -0.77 (0.28) .006 -0.55 (0.29) .062 
 Wave  0.09 (0.03) .001 0.67 (0.03) .024  0.09 (0.03) .001 0.06 (0.03) .051 
 Wave x cannabis use -0.02 (0.09) .781 0.00 (0.09) .995  -0.07 (0.09) .419 -0.08 (0.09) .374 
Between-person effects          
 Cannabis use          
  No use (ref)          
  < wkly use -0.42 (0.34) .220 -0.61 (0.35) .055  -0.61 (0.38) .112 -0.59 (0.36) .096 
  Wkly+ use -1.52 (0.61) .013 -1.23 (0.54) .021  -1.50 (0.69) .029 -1.09 (0.60) .070 
 Wave  0.78 (0.16) < .001 0.37 (0.12) .002  0.90 (0.18) < .001 0.31 (0.14) .021 
 Wave x cannabis use 0.04 (0.32) .891 0.17 (0.26) .511  0.01 (0.36) .969 0.09 (0.29) .768 
Within-person effects          
 Cannabis use          
  No use (ref)          
  < wkly use -0.11 (0.19) .553 -0.10 (0.20) .604  0.02 (0.19) .924 0.02 (0.20) .933 
  Wkly+ use -0.32 (0.36) .385 -0.21 (0.41) .598  -0.07 (0.37) .854 -0.13 (0.41) .757 
 Wave  0.08 (0.03) .005 0.08 (0.03) .014  0.08 (0.03) .006 0.07 (0.03) .022 
 Wave x cannabis use -0.02 (0.03) 0.822 0.01 (0.09) .995  -0.07 (0.09) .463 -0.07 (0.10) .473 
a
Adjusted for age at baseline, sex, unemployment, years of education, tobacco smoking, AUDIT score, heaviest past drinking (4+ times/week and no. 




    
Figure 1. Predicted mean (95% CI) immediate recall score (A) and delayed recall score (B) by wave 
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